ACT Capital Management LLC Invests $529,000 in Scholar Rock Holding Corporation $SRRK

ACT Capital Management LLC bought a new position in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 12,000 shares of the company’s stock, valued at approximately $529,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in SRRK. Orbis Allan Gray Ltd increased its position in shares of Scholar Rock by 1,034.5% during the fourth quarter. Orbis Allan Gray Ltd now owns 3,428,929 shares of the company’s stock worth $151,044,000 after purchasing an additional 3,126,677 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Scholar Rock by 124.5% during the third quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock worth $169,289,000 after purchasing an additional 2,521,022 shares in the last quarter. Holocene Advisors LP acquired a new stake in shares of Scholar Rock during the third quarter worth about $91,670,000. Norges Bank acquired a new stake in shares of Scholar Rock during the fourth quarter worth about $91,603,000. Finally, Siren L.L.C. increased its position in shares of Scholar Rock by 17.0% during the fourth quarter. Siren L.L.C. now owns 10,825,013 shares of the company’s stock worth $476,842,000 after purchasing an additional 1,575,008 shares in the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on SRRK. Piper Sandler lifted their target price on Scholar Rock from $51.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 4th. Raymond James Financial reiterated a “strong-buy” rating on shares of Scholar Rock in a research report on Tuesday, March 3rd. HC Wainwright lifted their target price on Scholar Rock from $58.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a research report on Tuesday, April 21st. Finally, Citigroup raised their price target on Scholar Rock from $55.00 to $58.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $56.00.

Scholar Rock Price Performance

Shares of SRRK opened at $46.95 on Thursday. Scholar Rock Holding Corporation has a twelve month low of $27.07 and a twelve month high of $52.19. The stock’s 50 day moving average is $47.67 and its two-hundred day moving average is $45.93. The firm has a market capitalization of $5.63 billion, a PE ratio of -13.08 and a beta of 0.69. The company has a current ratio of 8.64, a quick ratio of 8.64 and a debt-to-equity ratio of 0.71.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same quarter in the prior year, the firm earned ($0.67) earnings per share. Research analysts anticipate that Scholar Rock Holding Corporation will post -3.23 earnings per share for the current year.

Insiders Place Their Bets

In other Scholar Rock news, CEO David Hallal sold 30,615 shares of Scholar Rock stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $49.57, for a total value of $1,517,585.55. Following the sale, the chief executive officer owned 1,639,034 shares of the company’s stock, valued at approximately $81,246,915.38. The trade was a 1.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Akshay Vaishnaw sold 12,246 shares of Scholar Rock stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $49.57, for a total value of $607,034.22. Following the completion of the sale, the insider directly owned 630,542 shares in the company, valued at $31,255,966.94. This represents a 1.91% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 63,491 shares of company stock worth $3,147,249 over the last quarter. 13.30% of the stock is owned by company insiders.

Scholar Rock Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).